These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 11018853

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
    Delta Coordinating CommitteeMedical Research Council Clinical Trials Unit, University College London Medical School, UK., Delta Virology Committee.
    AIDS; 1999 Jan 14; 13(1):57-65. PubMed ID: 10207545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee.
    HIV Med; 2001 Jul 14; 2(3):181-8. PubMed ID: 11737399
    [Abstract] [Full Text] [Related]

  • 12. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB.
    AIDS; 2000 Jul 28; 14(11):1553-61. PubMed ID: 10983642
    [Abstract] [Full Text] [Related]

  • 13. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
    Katzenstein DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S, ACTG 302 Study Team.
    AIDS Res Hum Retroviruses; 2001 Feb 10; 17(3):203-10. PubMed ID: 11177402
    [Abstract] [Full Text] [Related]

  • 14. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.
    J Acquir Immune Defic Syndr; 2009 May 01; 51(1):37-46. PubMed ID: 19282782
    [Abstract] [Full Text] [Related]

  • 15. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM.
    AIDS; 1997 Feb 01; 11(2):169-75. PubMed ID: 9030363
    [Abstract] [Full Text] [Related]

  • 16. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS, DeMasi R, Hill AM.
    AIDS; 1998 Mar 26; 12(5):F23-8. PubMed ID: 9543436
    [Abstract] [Full Text] [Related]

  • 17. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 26; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

  • 18. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B, Wintergerst U, Notheis G, Eberle J, Gürtler L, Belohradsky BH.
    J Pediatr; 1997 Feb 26; 130(2):293-9. PubMed ID: 9042135
    [Abstract] [Full Text] [Related]

  • 19. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec 26; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 20. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr 01; 13(5):565-73. PubMed ID: 10203381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.